CAS154229-19-3MuscleBuildingSteroidsAbiraterone98%ForMetastaticCastration-resistantProstateCancerQuickDetails:ProductName:AbirateroneAlias:17-(3-Pyridyl)androsta-5,16-dien-3beta-olCASregisternumber:154229-19-3MolecularFormula:C24H31NOMolecularWeight:349.51MolecularStructure:CAS154229-19-3MuscleBuildingSteroidsAbirateroneBodybuildingSupplementsSteroidsAssay:98%Appearance:WhitepowderGrade:PharmaceuticalGradeStorage:Shading,confinedpreservationManufacturer:HezhongUsage:Itisindicatedforuseincombinationwithprednisoneasatreatmentformetastaticcastration-resistantprostatecancer.Description:Abirateroneisadrugusedincombinationwithprednisoneinmetastaticcastration-resistantprostatecancer(formerlyhormone-resistantorhormone-refractoryprostatecancer)--i.e.,prostatecancernotrespondingtoandrogendeprivationortreatmentwithantiandrogens.Itisformulatedastheprodrugabirateroneacetateandmarketedunderthetradename***.CadilaPharmaceuticalshasrecentlystartedmarketingAbirateroneacetateunderthetradenameAbretone.Afteranexpeditedsix-monthreview,abirateronewasapprovedbytheU.S.FoodandDrugAdministration(FDA)inApril2011.InPhaseIIItrials,itextendedmediansurvivalto14.8monthsversus10.9monthsplacebo,andthetrialwasstoppedbecauseofthesuccessfuloutcome.Application:Itisindicatedforuseincombinationwithprednisoneasatreatmentformetastaticcastration-resistantprostatecancer.IthasreceivedFDA(28April2011),EMA(23September2011),MHRA(5September2011)andTGA(1March2012)approvalforthisindication.[3][4][5][6]InAustraliaitiscoveredbythePharmaceuticalBenefitsSchemewhenbeingusedtotreatcastration-resistantprostatecancerandgivenincombinationwithprednisone/prednisolone(subjecttotheconditi***thatthepatientisnotcurrentlyreceivingchemotherapy,iseitherresistantorintolerantof***,hasaWHOperformancestatusof<2,andhisdiseasehasnotsincebecomeprogressivesincetreatmentwithPBS-subsidisedabirateronehascommenced).)